ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biologic agents"

  • Abstract Number: 1810 • 2017 ACR/ARHP Annual Meeting

    A Systematic Review of the Impact of Anti-Rheumatic Drugs upon Male Fertility and Paternal Exposure Peri-Conception

    Julia D Flint1, Maria Mouyis2 and Ian Giles3, 1Medicine, University College London, London, United Kingdom, 2Rheumatology Department, Northwick Park Hospital, London, United Kingdom, 3Centre for Rheumatology, University College London, Centre for Rheumatology, University College London, UK, London, United Kingdom

    Background/Purpose: There is limited evidence relating to the impact of disease modifying anti-rheumatic drugs (DMARDs) upon male fertility and on pregnancies conceived by men with rheumatic…
  • Abstract Number: 2491 • 2017 ACR/ARHP Annual Meeting

    Real-World Effectiveness and Safety of Subcutaneous Abatacept in Biologic-Naive Vs. Biologic-Experienced RA Patients: The Abatacept Best Care Study

    B Haraoui1, Janet E. Pope2, Isabelle Fortin3, Emmanouil Rampakakis4, John S. Sampalis5,6, Francoise Romeyer7, Joseph Atallah7 and Louis Bessette8, 1Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, 2Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, 3Centre de Rhumatologie de l'Est du Quebec, Rimouski, QC, Canada, 4JSS Medical Research, Montreal, QC, Canada, 5McGill University, Montreal, QC, Canada, 6JSS Medical Research, St-Laurent, QC, Canada, 7Bristol-Myers Squibb, Montreal, QC, Canada, 8Centre d'Osteoporose et de Rhumatologie de Quebec, Quebec, QC, Canada

    Background/Purpose: The efficacy and safety of subcutaneous (SC) abatacept in the management of rheumatoid arthritis (RA) has been demonstrated in numerous controlled clinical trials. However,…
  • Abstract Number: 542 • 2017 ACR/ARHP Annual Meeting

    Is There Any Difference in RA Patients for Methotrexate Use Vs. Leflunomide Use As a Concomitant Treatment with Biological and Targeted Synthetic Dmards in Turkbio Registry?

    Nevsun Inanc1, Gulsen Ozen2, Yasemin Yalçınkaya1, Ediz Dalkilic3, Suleyman Serdar Koca4, Gerçek Can5, Ahmet Karatas6, Yavuz Pehlivan7, Ayten Yazici8, Ayse Cefle9, Abdurrahman Tufan10, Servet Akar11, Soner Senel12, Burak Oz13, Nurullah Akkoc14 and Fatos Onen15, 1Departement of İnternal Medicine, Division of Rheumatology, Marmara University, Istanbul, Turkey, 2Rheumatology, Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, 3Department of Internal Medicine, Division of Rheumatology, Uludag University, School of Medicine, Rheumatology, Bursa, Turkey, 4Department of Rheumatology, Firat University School of Medicine, Elazig, Turkey, 5Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, 6Department of Rheumatology, Firat University, School of Medicine, Rheumatology, Elazig, Turkey, 7Department of Rheumatology, Uludag University, Bursa, Turkey, 8Rheumatology, Kocaeli University, Kocaeli, Turkey, 9Rheumatology, Kocaeli University, School of Medicine, Rheumatology, Kocaeli, Turkey, 10Internal Medicine-Rheumatology, Gazi University Medical School, Rheumatology, Ankara, Turkey, 11Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, Izmir, Turkey, 12Rheumatology, Kayseri Erciyes University, School of Medicine, Rheumatology, Kayseri, Turkey, 13Rheumatology, Firat University, School of Medicine, Rheumatology, Elazig, Turkey, 14Rheumatology, Private Practice, Rheumatology, İzmir, Turkey, 15Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey

    Background/Purpose: TURKBIO registry is the Turkish version of Danish DANBIO rheumatologic database which has been established in 2011. Demographic and clinical data including age, sex,…
  • Abstract Number: 1453 • 2017 ACR/ARHP Annual Meeting

    Impact of Biological and Targeted Synthetic Dmards on Work in Patients with Chronic Inflammatory Arthritides : A Meta Analysis of Randomized Controlled Trials and Controlled Cohorts

    Charlotte Traverson1, Amandine Tubery1, Charlotte Hua2, Françoise Barchechath-Flaisler1, Cédric Lukas3, Bernard Combe2, Jacques Morel2 and Cécile Gaujoux-Viala4, 1Rheumatology, Nîmes University Hospital, Nîmes, France, 2Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, 3Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, 4Rheumatology, Nîmes University Hospital and EA2415 Montpellier University, Nîmes, France

    Background/Purpose: The addition of biological (b) and new targeted synthetic (ts) DMARDs agents in chronic inflammatory arthritides (CIAs) therapeutic strategies has improved the possibility of…
  • Abstract Number: 1826 • 2017 ACR/ARHP Annual Meeting

    Secukinumab Achievement of Psoriatic Arthritis Disease Activity Score (PASDAS) Related Remission: 2-Year Results from a Phase 3 Study

    Laura C Coates1, Dafna D Gladman2, Peter Nash3, Oliver FitzGerald4, Arthur Kavanaugh5, Lawrence Rasouliyan6, Luminita Pricop7, Kevin Ding7 and Corine Gaillez8, 1Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 2Toronto Western Hospital, Toronto, ON, Canada, 3University of Queensland, Brisbane, Australia, 4St Vincent's University Hospital, Dublin, Ireland, 5UC San Diego School of Medicine, La Jolla, CA, 6RTI Health Solutions, Barcelona, Spain, 7Novartis Pharmaceuticals Corporation, East Hanover, NJ, 8Novartis Pharma AG, Basel, Switzerland

    Background/Purpose: Psoriatic arthritis (PsA) disease activity score (PASDAS) assessing multiple facets of PsA was demonstrated to distinguish treatment effect, perform better in statistical terms than…
  • Abstract Number: 2546 • 2017 ACR/ARHP Annual Meeting

    Secukinumab Decreases Arterial Wall Inflammation in Patients with Peripheral Spondyloarthritis

    Leonieke van Mens1, Simone Verweij2, Arno van Kuijk3, Erik Stroes2 and Dominique Baeten1, 1AMC, Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands, 2Vascular Medicine, Academisch Medisch Centrum, Amsterdam, Netherlands, 3Reade, Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands

    Background/Purpose: Patients with spondyloarthritis (SpA), a chronic inflammatory disease, have an increased cardiovascular risk, which is partly due to increased inflammatory activity in the arterial…
  • Abstract Number: 545 • 2017 ACR/ARHP Annual Meeting

    Incidence of Infusion Reactions to Intravenous Golimumab: Results from a Prospective, Real-World Community Registry

    Rafat Faraawi1, Andrew Chow2, Majed M M Khraishi3, Derek Haaland4, Milton F. Baker5, Cathy Tkaczyk6, Allen J Lehman7, Francois Nantel6 and Brendan Osborne6, 1McMaster University, Hamilton, ON, Canada, 2Credit Valley Rheumatology, Mississauga, ON, Canada, 3Faculty of Medicine, Memorial University of Newfoundland, St John's, NF, Canada, 4Rheumatology, Clinical Immunology & Allergy, McMaster University, Barrie, ON, Canada, 5VIHA, Victoria, BC, Canada, 6Medical Affairs, Janssen Inc., Toronto, ON, Canada, 7Janssen Inc., Toronto, ON, Canada

    Background/Purpose: Golimumab (GLM) is a monoclonal antibody targeting TNF-alpha, indicated for the treatment of adults with rheumatoid arthritis in combination with methotrexate (MTX).  GLM-IV is…
  • Abstract Number: 1456 • 2017 ACR/ARHP Annual Meeting

    Synergistic Reversal of Arthritis By Synoviocyte-Targeted Therapy and TNF Immunomodulation

    Christian Secchi1,2,3, Karen M. Doody2, Mattias N. D. Svensson2,4, Frances Humby5, Rebecca Hands5, Eugenio Santelli1,2, Cristiano Sacchetti2,6, Kuninobu Wakabayashi7, Dennis J. Wu8, Ardita Aliko9, Piotr Mydel9,10, Tsuyoshi Kasama7, David L. Boyle11, Francesco Galimi12, Michel L. Tremblay13, Gary S. Firestein6, Costantino Pitzalis5, Stephanie Standford8,14 and Nunzio Bottini2,4, 1Medicine, University of California San Diego, San Diego, CA, 2Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, 3Medicine, National Institute of Biostructures and Biosystems, University of Sassari Medical School, Sassari, Italy, 4Department of Medicine, University of California San Diego, La Jolla, CA, 5Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, 6Medicine, University of California San Diego, La Jolla, CA, 7Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan, 8University of California San Diego, San Diego, CA, 9University of Bergen, Bergen, Norway, 10Clinical Science, Broegelmann Research Laboratory, Bergen, Norway, 11University of California San Diego, La Jolla, CA, 12National Institute of Biostructures and Biosystems, University of Sassari Medical School, Sassari, Italy, 13Goodman Cancer Centre, McGill University, Montréal, QC, Canada, 14La Jolla Institute for Allergy and Immunology, La Jolla, CA

    Background/Purpose: Despite the availability of immunosuppressive disease-modifying anti-rheumatic agents (DMARDs), many rheumatoid arthritis (RA) patients still fail to achieve remission. Fibroblast-like synoviocytes (FLS) are non-immunological…
  • Abstract Number: 1828 • 2017 ACR/ARHP Annual Meeting

    Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 2-Year Results from a Phase 3 Study

    Karel Pavelka1, Alan J. Kivitz2, Eva Dokoupilova3, Ricardo Blanco4, Marco Maradiaga5, Hasan Tahir6, Alan Slade7, Yi Wang7, Susanne Rohrer8 and Brian Porter7, 1Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, 2Altoona Center for Clinical Research, Duncansville, PA, 3MEDICAL PLUS s.r.o., Uherske Hradiste, Czech Republic, 4Hospital Universitario Marqués de Valdecilla, Santander, Spain, 5Centro de Investigación de Tratamientos Innovadores de Sinaloa, Culiacán, Mexico, 6Barts Health NHS Trust, London, United Kingdom, 7Novartis Pharmaceuticals Corporation, East Hanover, NJ, 8Novartis Pharma AG, Basel, Switzerland

    Background/Purpose: Secukinumab (SEC) improved the signs and symptoms of AS in 2 Phase 3 studies (MEASURE 1 and 2).1,2 Here, we present interim results through…
  • Abstract Number: 2743 • 2017 ACR/ARHP Annual Meeting

    Requirement and Response Rates of Biologic Agents in Polyarteritis Nodosa (PAN)

    Omer Karadag1,2, Berkan Armagan2, Abdulsamet Erden2, Seerapani Gopaluni1, Alper Sari2, Sedat Kiraz2 and David Jayne3, 1Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, Cambridge, United Kingdom, 2Hacettepe University Vasculitis Center (HUVAC), Ankara, Turkey, 3Vasculitis and Lupus Clinic, Department of Medicine, University of Cambridge, Cambridge, United Kingdom

    Background/Purpose: Recent studies highlight the usefulness and necessity of biologic agents in the treatment of primary vasculitides. Evidence for the use of biologics in PAN…
  • Abstract Number: 88 • 2017 Pediatric Rheumatology Symposium

    Clinical Features and Frequency of Biologic use in Patients with Juvenile Dermatomyositis-associated Calcinosis

    Amir Orandi1, Vikas Dharnidharka2, Noor Al-Hammadi3 and Kevin Baszis1, 1Pediatric Rheumatology, Washington University in St. Louis School of Medicine, Saint Louis, MO, 2Pediatric Nephrology, Washington University in St. Louis School of Medicine, Saint Louis, MO, 3Division of Biostatistics, Washington University in St. Louis School of Medicine, St Louis, MO

    Background/Purpose: Calcinosis develops in an estimated 40% of patients with Juvenile Dermatomyositis (JDM). Conflicting studies have not definitively identified actionable risk factors or demonstrated that…
  • Abstract Number: 107 • 2016 ACR/ARHP Annual Meeting

    Improvement of Quality and Cost-Effectiveness of Rheumatology Care By Creating Long-Term Alliances with Pharmaceutical Companies

    M Van Houdenhoven (CEO, PhD, Prof)1, F.H.J. van den Hoogen (MD, PhD, Prof)2, K Bevers (MD, PhD)2, W.H. van der Laan (MD, PhD)2, J Van der Werf2, M Staub3 and B.J.F. Van den Bemt (PharmD, PhD)4, 1Sint Maartenskliniek, Nijmegen, Netherlands, 2Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, 3Purchasing department, Sint Maartenskliniek, Nijmegen, Netherlands, 4Department of Pharmacy, Sint Maartenskliniek, Nijmegen, Netherlands

    Background/Purpose:  Biological therapies have importantly contributed to controlling disease activity in patients with inflammatory rheumatic diseases. As the high costs of biologics are a threat…
  • Abstract Number: 1610 • 2016 ACR/ARHP Annual Meeting

    Safety, Tolerability, and Dose-Dependent Inhibition of T-Cell-Dependent Antibody Response with MEDI4920, a Novel, Engineered CD40L Antagonist: Results of a Single-Ascending Dose Study in Healthy Volunteers

    Marius Albulescu1, Jim Bush2, Firas Almazedi2, Ethan Grant3, Alex Godwood1, Robert Miday4, Krista Arbaugh4, Lisa H. Butler1, Michele Gunsior4, Jing Li5 and David Howe1, 1MedImmune, Cambridge, United Kingdom, 2Covance Clinical Research Unit, Leeds, United Kingdom, 3Translational Medicine, MedImmune, Gaithersburg, MD, 4MedImmune, Gaithersburg, MD, 5MedImmune, Mountain View, CA

    Background/Purpose: The CD40L/CD40 co-stimulatory pathway is important for T-cell-dependent antibody production. Previous clinical programs with intact monoclonal antibodies against CD40L have been discontinued due to…
  • Abstract Number: 2234 • 2016 ACR/ARHP Annual Meeting

    Economic Impact of Above-Label Dosing with Biologics in Patients with Moderate-to-Severe Psoriatic Arthritis

    Sergio Schwartzman1, Yunfeng Li2, Huanxue Zhou3, Vivian Herrera2 and Jacqueline B. Palmer2, 1Hospital for Special Surgery, New York, NY, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, 3KMK Consulting Inc, East Hanover, NJ

    Authors: S. Schwartzman*1, Y. Li2, H. Zhou3, V. Herrera2, J. Palmer2 Affiliations: 1Hospital for Special Surgery, New York, NY, US; 2Novartis Pharmaceuticals Corporation, East Hanover,…
  • Abstract Number: 2647 • 2016 ACR/ARHP Annual Meeting

    Drug Trough Serum Levels Rather Than Antidrug Antibodies Explain Disease Flares in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with TNF Inhibitors in Clinical Remission/Low Disease Activity: A One Year Prospective, Multicenter Study (INMUNOREMAR)

    Raimon Sanmarti1, Jose Inciarte-Mundo1, Paula Estrada2, Maria García Manrique3, Javier Narváez4, Antonio Gomez-Centeno3, Jesús Rodríguez-Moreno4, Mariona Pascal5 and Jordi Yagüe5, 1Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, 2Rheumatology Department, Hospital Moisès Broggi-Hospital General de L'Hospitalet - Consorci Sanitari Integral, Sant Joan Despí, Spain, 3Rheumatology Department, Hospital Parc Taulí, Sabadell, Spain, 4Rheumatology Department, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Spain, 5Immunology Department, Hospital Clinic de Barcelona, Barcelona, Spain

    Background/Purpose:  To determine predictive factors of disease flares, including drug trough serum levels and anti-drug antibodies (Ab) in patients with rheumatoid arthritis (RA) or polyarticular…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 26
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology